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ABSTRACT— Objectives. In this article we describe the long-term follow-up of patients 
with carcinoma in situ (CIS) of the urinary bladder and examine whether the extent of 
CIS, the presence of associated papillary tumors, or the response to treatment influence 
the course of the disease.
Methods. Fifty-two patients with CIS of the bladder, treated in a randomized prospec­
tive study, are described. In 23 patients with concomitant papillary tumors all macro- 
scopically visible lesions were completely resected transurethrally (TUR). CIS was histo­
logically confirmed in all patients by biopsy, 29 of whom had primary CIS. The patients 
were treated with intravesical mitomycin, bacille Calmette-Guérin (BCG)-RIVM or BCG- 
Tice and followed regularly by urine cytology, cystoscopy, and biopsy.
Results. Complete response was achieved in 65% of the patients. Of these respon­
ders, 24% later had a recurrence of CIS or a superficial tumor and 18% had progres­
sive disease (PD). In the nonresponding patients, progression occurred in 67%. In the 
whole group, PD was seen in 35% of the patients, and radical cystectomy was per­
formed in 21 %. The disease-related death rate was 13%. The risk for recurrence or PD 
was not higher in patients with more extensive CIS, defined as three or more positive 
biopsy results or when CIS was associated with papillary tumors compared to patients 
with one or two biopsy specimens positive for CIS or CIS alone. Nonresponding patients 
showed a significantly higher progression rate and cystectomy rate than responding pa­
tients (P = 0.0012 and 0.008, respectively).
Conclusions. CIS of the bladder is a malignancy with a poor prognosis, especially in 
patients not responding after intravesical treatment. Early detection and adjuvant in­
travesical treatment after TUR of concomitant papillary tumors are required. In patients 
not responding after intravesical treatment, radical surgery is necessary before pro­
gression occurs. The number of biopsies positive for CIS, not the presence of concomi­
tant superficial tumors, was an indicator for progression or recurrence.
Carcinoma in situ (CIS) of the urinary bladder 
was first described by Melicow.1 At cystoscopy, 
the urothelium may appear normal or may be red, 
granular, mossy, or pink. Therefore, the endo­
scopic diagnosis of CIS at an early stage may be 
difficult. Several investigators have reported that 
urinary cytology is a more reliable way to detect 
CIS and may give an indication of the extent 
and grade of the disease.2 Sensitive examinations
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to detect CIS are karyometry3 and flow cytometry 
of bladder washings.4 The most commonly affected 
sites are the trigone or floor of the bladder, in­
cluding the periurethral areas and the bladder 
neck. The posterior and lateral walls are also fre­
quently involved but in situ carcinoma is seldom 
found on the anterior wall or dome. Multiple sites 
of involvement are frequent.5 CIS potentially in­
volves the whole urothelium. Moreover, CIS of the 
urinary bladder morphometrically looks like an 
invasive bladder carcinoma6 and has the potential
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to progress into invasive bladder carcinoma. The 
percentage of patients with CIS who develop an 
invasive cancer is 50% to 83%.2,7'10 The time to 
progress from in situ to invasive carcinoma has 
been reported to be 18 to 77 months.11 Prognos­
tic factors for progression are multicentricity and 
extent of mucosal involvement.5 The predictive 
value for progression in patients with CIS associ­
ated with papillary disease is less clear. These pa­
tients with CIS associated with Stage Ta or T1 tu­
mors have a more varied course than those with 
CIS alone. Occasionally, transurethral resection 
with fulguration of adjacent urothelium will pro­
vide long-term control of focal CIS associated with 
early stage transitional cell carcinoma. More com­
monly, however, the disease is diffuse and associ­
ated with a higher risk of progression.5
CIS is classified as primary when it is not asso­
ciated with any previous or present history of pap­
illary tumor, as concomitant when it is present to­
gether with a papillary superficial tumor, and as 
secondary when it occurs during the follow-up of 
a papillary tumor.
The objective of this report was to determine 
whether the extent of CIS, the presence of con­
comitant papillary tumors, or treatment response 
influence the course of the disease.
MATERIAL AND METHODS
In this report, we describe 52 patients with pri­
mary CIS or CIS associated with pTa or pTl tu­
mors among a group of 469 patients with super­
ficial bladder carcinoma treated in a randomized 
prospective study.12 Analysis was performed for 
all 52 patients and of subgroups of patients. Sub­
groups were identified by the extent of CIS, the 
presence or absence of papillary tumors, and the 
response to intravesical treatment.
Biopsies of suspect areas as well as random biop­
sies were taken, and complete transurethral resec­
tion (TUR) of all visible associated papillary tu­
mors was performed. The presence of CIS was 
confirmed by a referee pathologist. None of the 
patients was previously treated for CIS. Patients 
were randomized to one of three treatment groups. 
In group I, mitomycin (Mutamycin, Kyowa, Chris- 
tiaens) 30 mg in 50-mL saline was given once a 
week for 4 weeks and thereafter once a month for
5 months. Intravesical immunotherapy was done 
using bacille Calmette-Guerin (BCG)-RIVM 
(group II, the Dutch strain, Lundbeck) or BCG- 
Tice (group III, Oncotice, Organon Teknika). BCG 
(5 X 108 bacilli in 50-mL of saline) was given 
once a week for 6 consecutive weeks. Instillations 
were started between 7 and 15 days after diagno­
sis of CIS. After completion of the instillation ther- 
apy, patients were followed every 3 months by 
urine cytology, cystoscopy, and eventually biopsy. 
Tumor recurrence was histologically proven by 
biopsy. If t}ie urine cytology was positive with neg­
ative findings at cystoscopy, random biopsies were 
taken. In case of a first recurrent tumor or CIS at
3 or 6 months in BCG-treated patients, a second 
6-week course of BCG was given. In mitomycin- 
treated patients, three additional monthly instilla­
tions were given in case of a first recurrence at
6 months. In case of a first recurrence at or after
9 months and in case of progression, the patient 
went off study and was followed for survival. Pro­
gression was defined as muscle-invasive bladder 
cancer, involvement of prostatic tissue, or the de­
velopment of métastasés. Complete response was 
defined as negative cystoscopy, negative cytology, 
and negative biopsy, which means there was no 
CIS or a papillary tumor in the resected tissue.
Statistical analysis was performed using Stu­
dent’s t test and chi-square test for numerical and 
categorical data, respectively.
RESULTS
Of the 52 patients with CIS, 29 had primary CIS 
and 23 had concomitant superficial tumors (pTa in
11 and pTl in 12 patients). Fifteen patients (29%) 
received mitomycin, 15 (29%) received BCG-RIVM, 
and 22 (42%) received BCG-Tice. Of the 52 pa­
tients, 34 (65%) showed a complete response after 
TUR and intravesical treatment. Of the 34 respon­
ders, 19 (56%) remained free of disease, with a 
mean follow-up of 45 months (range, 11 to 81). Re­
currence of a superficial papillary tumor or CIS was 
seen in 8 of 34 patients (24%): 2 patients had re­
current CIS, 6 patients developed a superficial pap­
illary tumor without CIS (3 had pTa tumors, 3 had 
pTl tumors). Of these 6 patients, 3 previously also 
had a papillary tumor associated with the CIS. The 
median time to recurrence was 31 months (95% 
confidential interval [Cl], 9 to 53 months). Pro­
gressive disease (PD) in responders occurred in 6 
patients (18%) after a median duration of 29 months 
(95% Cl, 11 to 70 months). Two patients had lymph 
node métastasés, of whom 1 also had lung métas­
tasés. In 3 patients with progression, a cystectomy 
was performed. In 1 of these patients, the resected 
specimen also showed CIS in one ureter.
Of the 18 patients (35%) who had no response 
after one or two treatment courses, 6 (33%) had 
persistent CIS without progression into invasive 
bladder cancer, and 12 (67%) nonresponders 
showed PD after a mean time of 14 months (95% 
Cl, 6 to 28 months). Of the 6 patients with
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TABLE I. Patient outcome of all patients with CIS
Follow-up (mo)
Complete response (no, %) 
Progressive disease (no, %) 
Time to progression (mo) 
Cystectomy rate (no, %)
Time to cystectomy (mo) 
Disease-related death (no, %) 
Time to death (mo)
Total 
(n = 52)
45 (15-72) 
34/52, 65% 
18/52, 35% 
1 9 (6—7 0]
1 1/52, 21% 
19 (10-37) 
7/52, 13% 
32 (13-74)
Mitomycin
(n-15)
41 (15-65) 
9/15, 60% 
4/15, 27%
1 1 (6-13] 
2/15, 13% 
15 (14-16) 
2/15, 13% 
18(18-18)
No. of Patients
BCG-RIVM
(n = 15)
48(15-72) 
1 1/15,73% 
7/15, 47% 
23 (6-70) 
5/15, 33% 
19(10-27) 
3/15, 20%
BCG-Tice 
(n = 22)
47 (21-72) 
14/22, 64% 
7/22, 32% 
20 (6-44) 
4/22, 1 8% 
22 (10-37) 
2/22, 9%
36(14-74) 41 (33-50)
BCG 
in - 3 7 )
48(15-72) 
25/37,68% 
14/37, 38% 
21 (6-70) 
9/37, 24% 
20 (10-37) 
5/37, 14% 
38(14-74)
Mitomycin 
versus BCG 
P Value
0.36
0.84
0.66
0.24
0.61
0.48
1.00
0.25
Key.’ CIS = Carcinoma in siiu; B C G  = badile  Cahnette-Guérin.
TABLE II. Patient outcome related to the amount of CIS
1-2 Small Spots P
of CIS >3 Spots Value '
No. of patients 30 22
Follow-up (mo) 46(14-72) 43 (14-78) 0.30
Complete response (no, %) 21/30, 70% 13/22,59% 0.60
Recurrence rate in responders (no, %) 5/21, 24% 3/13,23% 1.00
Time to recurrence (mo) 36 (9-53) 24(16-45) 0.33
Disease-free interval (mo) 38 (7-71) 37 (11-81) 0.33
Progressive disease (no, %) 9/30, 30% 9/22,41% 0.60
Time to progression (mo) 19(6-70) 19 (6-43) 0.63
Cystectomy rate (no, %) 5/30, 17% 6/22,27% 0.56
Time to cystectomy (mo) 22 (10-37) 17 (10-26) 0.36
Disease-related death (no, %) 3/30, 10% 4/22, 20% 0.66
Time to death (mo) 47 (17-74) 21 (13-32) 0.29
persistent CIS, 3 underwent a cystectomy. In one 
resected specimen CIS was histologically con­
firmed in both ureters and in the prostatic urethra. 
One patient had CIS in the prostatic tissue and 
right ureter. Two patients were treated with one or 
more courses of intravesical BCG; in 1 patient this 
was followed by monthly instillations of epiru- 
bicin for more than 2 years. One patient was not 
treated further. Disease-related death was not seen 
in these 6 patients.
In the 12 nonresponders who showed progres­
sion, treatment was as follows: 5 underwent a rad­
ical cystectomy; 3 were treated with external ra­
diotherapy; 1 patient had positive lymph nodes at 
laparotomy and died within 6 months, disease re­
lated; 1 patient with lymph node métastasés was 
treated with chemotherapy: methotrexate, vin­
blastine, doxorubicin, and cisplatin (MVAC), fol­
lowed by external irradiation; and 2 patients were 
not treated because of a poor clinical condition 
and because of the probability of liver métastasés. 
Of the 5 patients who were operated on, 2 were 
free of disease with a follow-up of 3.5 and 4 years 
and 3 developed métastasés later, of which 2 re­
ceived treatment with MVAC and 1 patient died 
of a disease-related condition after the cystectomy.
Of the 12 patients with PD, 5 died of a disease- 
related condition.
In the total group, 18 of 52 (35%) patients 
showed PD after a median duration of 19 months 
(95% Cl, 6 to 70 months). Eleven of 52 patients 
(21%) underwent a radical cystectomy. During 
the follow-up period, 16 patients died: 7 (13%)
deaths were disease related, 5 among the nonre­
sponders. Follow-up of the whole group and treat­
ment groups is summarized in Table I.
There were no significant differences in response 
rate, progression rate, or time to progression be­
tween the BCG-RIVM- and BCG-Tice-treated 
patients. When comparing the mitomycin-treated 
patients with the BCG-treated patients, we could 
not find any significant differences (Table I).
With regard to the extent of CIS, comparison of 
patients with one or two small positive biopsy results 
versus three or more positive biopsy results of CIS 
showed no significant differences in response rate, 
progression rate, or time to progression (Table II). 
Also, the recurrence rate and progression rate of the 
patients with primary CIS versus CIS associated 
with PTa tumors versus CIS associated with PT1 
tumors were not significantly different (Table III). 
Significant differences could only be found when
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TABLE III. Primary carcinoma in situ (CIS) versus CIS with pTa versus CIS with pT l
1 p Value P Value P Value
Primary CIS (I versus II) CIS + pTa (II versus III) CIS + p H  (I versus 111]
No. of patients 29
Follow-up (mo)
Complete response (no, %)
Recurrence rate in responders [no, %)
Time to recurrence (mo)
Disease-free interval (mo)
Progressive disease (no, %)
Time to progression (mo)
Cystectomy rate (no, %)
Time to cystectomy (mo)
Disease-related death (no, %)
Time to death (mo)
42 (12-72) 0.06 55 (33-81) 0.07 42 (17-65) 0.91
19/29,66% 0.95 8/11, 73% 0.67 7/12,58% 0.94
4/19, 21% 0.18 4/8, 50% 0.08 0/7, 0 % 0.54
31 (16-53) 0.81 29 (9-52) » t  ^ » « «
31 (7-72) 0.98 38 (9-81) 0.63 42 (13-61) 0.65
10/29, 34% 0.95 3/11, 27% 0.67 5/12,42% 0.94
20 (6-70) 0.50 21 (11-26) 0.30 16 (6-43) 0.54
5/29, 17% 0.38 4/11, 36% 0.37 2/ 12, 17% 1.00
16(10-24) 0.08 27 (16-37) 0.06 (10-14) 0.25
5/29, 17% 0.35 0 0.48 2/12, 17% 1.00
31 (13-74) • • * 4 * Ì 33 (17 49) 1.00
TABLE IV. Responders versus nonresponders
Responders Nonresponders P Value
No. of patients 34 18
Follow-up (mo) 48(15-75) 40 (13-65) 0.15
Recurrence rate in responders (no, %) 8/34, 24%
Time to recurrence (mo) 31 (9-53)
Progressive disease (no, %) 6/34, 18% 12/18,67% 0.0012
Time to progression (mo) 29(11-70) 1 4 (6-28) 0.09
Cystectomy rate (no, %) 3/34, 9% 8/18, 44% 0.008
Time to cystectomy (mo) 19 (16-24) 19 (10-37) 0.84
Disease-related death (no, %) 2/34, 6% 5/18, 28% 0.076
Time to death (mo) 45 (17-74) 26 (13-49) 0.70
comparing treatment responders to nonresponders 
(Table IV). The number of patients who developed 
PD and who underwent radical cystectomy 
was significantly higher in the nonresponders 
(P = 0.0012 and 0.008, respectively).
COMMENT
Early detection of CIS of the bladder has been 
considerably improved by cytologic examination 
of the urine and multiple biopsies of normal- and 
abnormal-looking bladder mucosa. The clinical 
management, however, remains a problem, since 
uncertain biologic behavior of CIS provides no 
firm basis for categorical treatment recommenda­
tions. In most instances nowadays, clinicians ini­
tiate intravesical immunotherapy or chemother­
apy with the aim to eradicate CIS, to prevent the 
development of muscle-invasive bladder cancer, 
and to prevent or delay cystectomy. In patients 
who achieved a complete remission with intra­
vesical therapy, the cystectomy rate was signifi­
cantly lower and the time to cystectomy longer 
compared with the nonresponders.10 Long-term
benefit of intravesical chemotherapy and im­
munotherapy for carcinoma in situ has also been 
reported.13'14
In our report we examined several prognostic 
factors. The extent of CIS had no prognostic sig­
nificance in our series. With regard to the absence 
or presence of concomitant papillary tumors, it is 
assumed that concomitant CIS behaves more fa­
vorably than primary CIS because it is detected 
and treated earlier.15 On the other hand, concomi­
tant high-grade pTl tumors might contribute more 
to PD than the CIS component does, even when a 
complete TUR had taken place.16’17 Our analysis 
of patients with primary CIS versus patients with 
concomitant CIS with either pTa tumors or pTl 
tumors showed no difference in treatment response 
and course of the disease. Significant differences 
could only be found between responders and non­
responders, detrimental to the nonresponders, 
which will indicate a very intensive follow-up and 
often more aggressive treatment. Other reports 
confirm our experience with patients who failed 
the registered treatment. Their clinical behavior
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differs significantly, with a higher progression and 
cystectomy rate, a shorter time to cystectomy, and 
a higher disease-related death rate.10’15’18’19
When we compare the results of this report with 
the prognosis of patients with papillary tumors 
alone, we conclude that CIS of the bladder has a 
more malignant behavior than high-risk papillary 
tumors; the percentage of PD in our report is 35% 
in patients with CIS versus 18% in 62 patients 
with pTl grade 3 tumors without CIS treated in 
the same protocol12 (unpublished data after 5 
years of follow-up). In the literature, the percent­
age of PD in high-grade, high-stage tumors is 20% 
to 30%.16 Although the percentage of complete re­
sponse in this, as in other studies, is high (60% to 
89%),5,20,21 CIS still remains a highly malignant 
disease with the potential to involve the whole 
urothelium and to develop into PD.
It is important to realize that histologic criteria 
of CIS were not clearly defined in the past. Today, 
consensus has been achieved that only grade 3 CIS 
should be called CIS and all other atypical cellular 
patterns of the epithelial cells should be inter­
preted as atypia (or dysplasia).22 Furthermore, 
studied patient groups with CIS are often very 
small, as in this report. The results mentioned 
herein explain why patients with CIS require ad­
juvant treatment with intravesical chemotherapy 
or immunotherapy and why early detection, early 
treatment, and careful follow-up are necessary.
CONCLUSION
CIS of the bladder is known as a malignancy 
with a poor prognosis and a high risk to develop 
into invasive bladder cancer. This report confirms 
the poor prognosis, especially in nonresponding 
patients. Early radical cystectomy should be con­
sidered in nonresponding patients to avoid further 
progression into muscle invasive disease and 
metastases. In this study, the treatment regimen, 
the extent of CIS, and the presence of papillary tu­
mors did not influence the course of the disease.
W i m  P.J. W it je s ,  M .D . .
Department of Urology 
University Hospital Nijmegen
P.O. Box 9101 
6500 HB Nijmegen, The Netherlands
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EDITORAL COMMENT
The unpredictability of carcinoma in situ (CIS) is a clini­
cally important dilemma. This review of 52 patients with CIS 
is derived from an original series of 469 patients previously 
considered to be at relatively low risk of disease recurrence. 
The observed 11% incidence of CIS is similar to that re­
ported in the United States.1 This study clearly confirms that 
even with effective intravesical treatment, CIS carries a poor 
prognosis. With an average follow-up of 45 months, disease 
progression occurred in 35% of patients and disease-related 
death in 13%. Most patients (65%) had complete response to 
intravesical therapy, but even with complete response, 18% 
subsequently progressed and 6% died of the disease. This 6% 
mortality is equal to that reported for early cystectomy in pa­
tients with CIS. Nonresponders fared significantly worse, 
with 67% of patients having disease progression and 28% of 
patients dying of disease despite the frequent use of cystec­
tomy. These data clearly show that residual CIS after intra­
vesical therapy is an ominous prognostic sign and supports 
the recommendation for cystectomy.
The timing of cystectomy is critical, and in this study av­
eraged 19 months in both the responder and nonresponder 
subgroups. The earliest cystectomy was done 10 months fol­
lowing initiation, of intravesical therapy. Although delay in 
cystectomy may preclude surgical cure, we can also make the 
mistake of removing bladders prematurely. With bacille Cal­
mette-Guérin (BCG) immunotherapy, several investigators 
have found that patients with residual CIS at 3 months of fol­
low-up can have complete response by 6 months. Southwest 
Oncology Group investigators have demonstrated that three 
additional BCG instillations given at 3 months significantly 
increase the complete response rate at 6 months. Based on 
these data, I recommend postponing cystectomy until 6 
months unless patients have evidence of increasing disease. 
With residual disease at 6 months, however, timely cystec­
tomy or alternate therapy is essential.
Previous authors have suggested that extensive diffuse CIS 
is more commonly symptomatic and more likely to be associ­
ated with progression.2 Focal CIS, on the other hand, has been 
reported to have an incidence of invasion as low as 8% in pa­
tients followed for as long as 16 years.3 In the present study, 
no statistically significant worsening of prognosis was seen in 
patients with more extensive disease. However, those with ex­
tensive disease had a lower response rate (by 11%), shorter 
time to recurrence (by 1 year), higher incidence of progressive 
disease (11%), higher cystectomy rate ( 10%), and higher dis­
ease-related mortality (10%). Although these differences are 
not statistically significant, it is incorrect to conclude that this 
study has demonstrated that extent of CIS does not correlate 
with recurrence or progression. A study of 52 patients has 
only sufficient power to detect a 35% difference in prognosis.
The authors were unable to confirm that associated T1 
transitional cell carcinoma carried a worse prognosis, despite 
numerous reports that high-grade invasive transitional cell 
carcinoma of the lamina propria has an ominous prognosis. 
In this study, the incidence of disease progression was 35% 
in patients with  CIS versus 18% in patients with grade III T1 
disease (P <0.04, Fisher’s exact test). Therefore, increased risk 
of disease progression alone is insufficient justification for 
primary cystectomy in patients with grade III T1 transitional 
cell carcinoma. Newer schedules of BCG induction  (“6+3” 
weekly instillations at 1 week and 3 months following tum or 
resection, respectively) and  m ain tenance  schedules  us ing  
three weekly treatments at 6-m onth  intervals have signifi­
cantly improved complete response rates and long-term re­
sults in patients with CIS and  Ta-Tl transitional cell carci­
noma compared with  the results reported  in  this study. 
Therefore, despite documented risk of disease progression in 
patients with CIS and grade III, Stage T1 transitional cell car­
cinoma, I believe that patients should be offered the option of 
a 3- to 6~month trial of BCG immunotherapy. As emphasized 
by the authors, careful biopsy studies for occult invasive dis­
ease and meticulous follow-up are required, and p rom pt cys­
tectomy should be considered in nonresponding patients.
Donald L. Lamm 
Department of Urology 
Robert C. Byrd Health Sciences Center of
West Virginia University
P.O. Box 9251 
Morgantown, WV 26506-9251
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